Vast Eyes Hong Kong IPO as Chinese AI Unicorn Gains Momentum 
FleetPartners Shares Jump After A$760 Million Takeover Proposal From Pacific Equity Partners 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
WestJet Cancels 86 Flights as CUPE Strike Threat Disrupts Travel 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
Alibaba Stock Jumps as Qwen 3.8-MAX AI Model Intensifies China's AI Race 
SpaceX Earnings Preview: Bernstein Says 4 Key Factors Will Drive Long-Term Valuation 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
Meta Cuts Wipro Outsourcing by 25% After AI-Led Restructuring 
T-Mobile Executives Reportedly Oppose $300 Billion Deutsche Telekom Merger 
Capital One Says AML Review Led to Closure of Trump Organization Accounts 
Boeing Stock Jumps as FAA Certifies 737 MAX-7 After Years of Regulatory Review 
Colgate-Palmolive Reaffirms 2026 Sales Outlook Despite Weak North America Demand 
Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
LEXINGTON, Mass., April 04, 2018 -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on April 2, 2018 it issued inducement awards to five new employees.
These awards were made under T2 Biosystems’ Inducement Award Plan (the "Inducement Plan"), which was adopted by the company’s Board of Directors on March 1, 2018 and provides for the granting of equity awards to new employees of T2 Biosystems. The inducement awards consist of options to purchase 49,000 shares of T2 Biosystems common stock and have a ten-year term. The exercise price of the options is $6.32, which was the per-share closing price of T2 Biosystems common stock on the Nasdaq Capital Market on April 2, 2018. The options vest over a four-year period, with 25% vesting on the first anniversary of the employee’s date of hire and the remainder vesting in equal monthly installments over the three years thereafter. The award was approved by the independent compensation committee of T2 Biosystems’ board of directors and was granted as an inducement material to the new employee entering into employment with T2 Biosystems in accordance with Nasdaq Marketplace Rule 5635(c)(4).
About T2 Biosystems
T2 Biosystems, an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, improves patient care and reduces the cost of healthcare by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, T2Candida® Panel, and the T2Bacteria® Panel and are powered by the proprietary T2 Magnetic Resonance technology, or T2MR®. T2Bacteria Panel is commercially available in Europe and other countries that accept the CE Mark and is available for research use only in the U.S. For more information, please visit www.t2biosystems.com.
T2 Biosystems Media Contact:
Amy Phillips, Feinstein Kean Healthcare
[email protected]
412-327-9499
T2 Biosystems Investor Contact:
Chris Brinzey, Westwicke Partners
[email protected]
339-970-2843
